RemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative

Simply Wall St.06-21

Earlier in June 2026, RemeGen announced that China’s National Medical Products Administration granted full approval for telitacicept in Sjögren’s disease and conditional approval in IgA nephropathy, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645095987?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-21 01:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645095987","market":"sg","top_or_hot":-1,"title":"RemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative","media":"Simply Wall St.","content":"<div>\n<p>Earlier in June 2026, RemeGen announced that China’s National Medical Products Administration granted full approval for telitacicept in Sjögren’s disease and conditional approval in IgA nephropathy, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-81-after-expanded-telitacicept-appr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-21 01:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-81-after-expanded-telitacicept-appr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in June 2026, RemeGen announced that China’s National Medical Products Administration granted full approval for telitacicept in Sjögren’s disease and conditional approval in IgA nephropathy, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-81-after-expanded-telitacicept-appr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIPO","symbol_name":"Defiance AI and Power Infrastructure ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-81-after-expanded-telitacicept-appr","article_id":"2645095987","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-is-down-81-after-expanded-telitacicept-appr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645095987","pubTimestamp":1781977059,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in June 2026, RemeGen announced that China’s National Medical Products Administration granted full approval for telitacicept in Sjögren’s disease and conditional approval in IgA nephropathy, both supported by positive Phase 2 and Phase 3 clinical data.\nThese decisions expand telitacicept to five approved autoimmune indications in China, underscoring the clinical breadth of RemeGen’s first-in-class BLyS/APRIL dual-target biologic.\nWe’ll now examine how this broadened telitacicept...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIPO":"Defiance AI and Power Infrastructure ETF","BK1583":"高瓴概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK1161":"生物科技","AGIX":"通用人工智能 ETF-AGIX","BK1574":"生物医药B类股","ARTY":"ISHARES FUTURE AI & TECH ETF","09995":"荣昌生物"},"translate_title":"RemeGen(SEHK：9995)在中国扩大Telitacicept批准重塑其管道叙事后下跌8.1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":0.9,"CHAT":0.62,"AIPO":0.72,"ARTY":0.62,"AGIX":0.62},"content_text":"Earlier in June 2026, RemeGen announced that China’s National Medical Products Administration granted full approval for telitacicept in Sjögren’s disease and conditional approval in IgA nephropathy, both supported by positive Phase 2 and Phase 3 clinical data. These decisions expand telitacicept to five approved autoimmune indications in China, underscoring the clinical breadth of RemeGen’s first-in-class BLyS/APRIL dual-target biologic. We’ll now examine how this broadened telitacicept label, especially the new IgA nephropathy indication, reshapes RemeGen’s investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementWhat Is RemeGen's Investment Narrative?For anyone considering RemeGen, the core belief now is that this is becoming a commercial-stage China biotech with a deep, de‑risked autoimmune and oncology portfolio rather than a single‑asset story. The new Sjögren’s disease approval and conditional IgA nephropathy nod extend telitacicept to five indications in China, reinforcing the company’s shift from pipeline build‑out to lifecycle management. In the near term, key catalysts still sit around how quickly these new labels convert into prescription uptake and whether Vor Bio can progress telitacicept toward ex‑China approvals. At the same time, the recent share price pullback despite solid profitability highlights that investors remain focused on execution risks: competitive intensity in autoimmune, the conditional nature of IgAN approval, high non‑cash earnings, and insider selling. This latest news raises the stakes on how convincingly RemeGen can turn approvals into durable, high‑quality earnings. However, one risk many shareholders may be underestimating is the conditional IgAN approval and what it implies for future data needs.\n\nDespite retreating, RemeGen's shares might still be trading 39% above their fair value. Discover the potential downside here.Exploring Other PerspectivesSEHK:9995 1-Year Stock Price Chart The Simply Wall St Community’s single fair value estimate clusters near HK$112.08, while the market price sits much lower, hinting at perceived undervaluation. Yet, as discussed above, the conditional nature of IgAN approval and dependence on successful commercialization could still weigh heavily on how RemeGen’s performance ultimately unfolds, so it is worth examining several viewpoints before deciding how this aligns with your own expectations.Explore another fair value estimate on RemeGen - why the stock might be worth just HK$112.08!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your RemeGen research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.Our free RemeGen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate RemeGen's overall financial health at a glance.Curious About Other Options?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645095987","isCrawlerRequest":true}